Promoted Content
Promoted Content

Find Approved Drugs for Pulmonary/Respiratory Diseases in Clinical Development


All Data

Filters Filter refresh
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter

            Product Type Full Screen

            Companies Full Screen

            Virtual BoothSanofi Active Ingredient Solutions cover both APIs sales & CDMO.

            Contact the Supplier

            Lead Product(s): Dupilumab

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Dupixent

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 17, 2020


            DUPIXENT® is a fully humanised monoclonal antibody that inhibits signaling of IL-4 and IL-13 proteins and is not an immunosuppressant. It is the only biologic approved in Canada to treat severe asthma with type 2/eosinophilic phenotype, or oral corticosteroid-dependent asthma.